1.
Weatherall DJ, Clegg JB: The Thalassaemia Syndromes, ed 4. Oxford, Blackwell Science, 2001.
2.
Taher A, Isma’eel H, Cappellini MD: Thalassaemia intermedia: revisited. Blood Cells Mol Dis 2006;37:12–20.
3.
Thein SL: Genetic insights into the clinical diversity of beta thalassaemia. Br J Haematol 2004;124:264–274.
4.
Hall GW, Barnetson RA, Thein SL: Beta thalassaemia in the indigenous British population. Br J Haematol 1992;82:584–588.
5.
Jamet D, Pissard S, Blouch MT, Berthou C, De Braekeleer M, Abgrall JF: β-Thalassemia in the indigenous population of Brittany: identification of three rare mutations. Haematologica 2006;91:1418–1419.
6.
Thein SL, Wainscoat JS, Sampietro M, Old JM, Cappellini D, Fiorelli G, Modell B, Weatherall DJ: Association of thalassaemia intermedia with a beta-globin gene haplotype. Br J Haematol 1987;65:367–373.
7.
Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB: Rapid detection of α-thalassaemia deletions and α-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol 2000;108:295–299.
8.
Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
9.
Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
10.
Cai SP, Eng B, Francombe WH, Olivieri NF, Kendall AG, Waye JS, Chui DH: Two novel beta-thalassaemia mutations in the 5′ and 3′ noncoding regions of the beta-globin gene. Blood 1992;79:1342–1346.
11.
Eng B, Waye JS, Chui DH: The T→C substitution at nucleotide +1570 of the beta-globin gene is a polymorphism (letter; comment): Blood 1992;80:1365.
12.
Hall GW, Thein S: Nonsense codon mutations in the terminal exon of the β-globin gene are not associated with a reduction in β-mRNA accumulation: a mechanism for the phenotype of dominant β-thalassaemia.Blood 1994;83:2031–2037.
13.
Romão L, Inácio A, Santos S, Avila M, Faustino P, Pacheco P, Lavinha J: Nonsense mutations in the human beta-globin gene lead to unexpected levels of cytoplasmic mRNA accumulation. Blood 2000;96:2895–2901.
14.
Shaanan B: Structure of human oxyhaemoglobin at 2.1 A resolution. J Mol Biol 1983;171:31–59.
15.
Tame JR, Vallone B: The structures of deoxy human haemoglobin and the mutant Hb Tyrα42His at 120 K. Acta Crystallogr D Biol Crystallogr 2000;56:805–811.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.